This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast And Market Analysis Event-Driven Update

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of rheumatoid arthritis drug performance in India

- Obtain sales forecast from 2011-2022 in India

Table of Contents

1 Table of Contents 4



1.1 List of Tables 6



1.2 List of Figures 6



2 Introduction 7



2.1 Catalyst 7



2.2 Related Reports 8



3 Disease Overview 10



3.1 Etiology and Pathophysiology 10



3.1.1 Etiology 10



3.1.2 Pathophysiology 10



3.1.3 Prognosis 13



3.1.4 Quality of Life 13



3.2 Symptoms 14



4 Disease Management 15



4.1 Treatment Overview 18



4.2 India 22



4.2.1 Diagnosis 22



4.2.2 Clinical Practice 22



5 Competitive Assessment 24



5.1 Overview 24



5.2 Strategic Competitor Assessment 24



5.3 Product Profiles - Major Brands 26



5.3.1 Enbrel (etanercept) 26



5.3.2 Remicade (infliximab) 32



5.3.3 Orencia (abatacept) 36



5.3.4 Actemra/RoActemra (tocilizumab) 40



5.3.5 Rituxan/MabThera (rituximab) 44



5.3.6 Methotrexate Sodium (numerous generic names) 48



5.3.7 DMARDs 51



6 Opportunity and Unmet Need 52



6.1 Overview 52



6.2 Unmet Needs 53



6.2.1 More rheumatologists in the field and physician knowledge of the disease 53



6.2.2 More cost-effective therapies through oral formulation and biosimilars 53



6.2.3 The development of predictive tests and discovery of biomarkers 54



6.2.4 The discovery of curative therapies 54



6.2.5 Improved drug safety and efficacy profiles 54



6.3 Gap Analysis 55



6.4 Opportunities 56



6.4.1 Predictive tools for diagnosis and treatment 56



6.4.2 Target specificity 56



7 Pipeline Assessment 57



7.1 Overview 57



7.2 Promising Drugs in Clinical Development 58



8 Market Outlook 60



8.1 India 60



8.1.1 Forecast 60



8.1.2 Key Events 62



8.1.3 Drivers and Barriers 63



9 Appendix 65



9.1 Abbreviations 65

2 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs